Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a "Watchful Waiting" and Resistance Population
Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a
bigger pie in Prostate cancer & Finding its niche in crowded BC market
Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the race?
View full press release